The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma.
Steven G. DuBois
No relevant relationships to disclose
M. Shelly Allen
No relevant relationships to disclose
Melissa Bent
No relevant relationships to disclose
Joan Hilton
No relevant relationships to disclose
Fabienne Hollinger
No relevant relationships to disclose
Jesse Courtier
No relevant relationships to disclose
Randall Hawkins
No relevant relationships to disclose
Yael P. Mosse
No relevant relationships to disclose
Katherine K. Matthay
Consultant or Advisory Role - Jubilant Draximage (U)